Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $537K fell 20.4% year over year, behind the -9.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at +26.6% a year.

Context

  • Depreciation & amortization amounted to 191.0% of revenue in FY2025, down 951.5 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -20.4% toward the trailing-twelve-month pace of -9.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$537K-4.8% QoQ
Last fiscal yearDec 2025
$2.48M+8.7% YoY
LTMMar 2026
$2.35M-9.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.4%——
1 year+8.7%——
3-year CAGR+26.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
2.48M USD
Year-over-year change
+8.7%
4-year CAGR
+20.1%

Depreciation & Amortization vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.8% is the 5th highest of 7, against a peer median of -1.7%.
  • Depreciation & amortization amounts to 180.4% of revenue for INBX, versus a peer median of 41.3%.
INBX Competitors
Depreciation & Amortization for INBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GENBGenerate Biomedicines, Inc.FY2025$13.18M USD-14.1%—41.3%
IMTXImmatics N.V.LTM Mar 2026€12.04M EUR-2.6%+21.9%32.3%
ABSIAbsci CorporationLTM Mar 2026$11.4M USD-12.6%-3.4%620.8%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$3.73M USD+10.4%+5.3%3333.9%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$2.35M USD-9.8%+26.6%180.4%
JANXJanux Therapeutics, Inc.LTM Mar 2026$2.03M USD-0.8%+34.1%9.4%
TECXTectonic Therapeutic, Inc.LTM Mar 2026$1.68M USD+3.1%+11.0%—
Peer median (excluding INBX) —-1.7%+11.0%41.3%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.13M2.19M1.8M200K1.3M
Cost of Revenue2.69M110.19M1.19M2.29M2.48M
Gross Profit4.44M(107.99M)609K(2.09M)(1.18M)
Gross Margin62.3%-4926.7%33.8%-1042.5%-91.0%
Research & Development71.44M110.19M190.65M203.74M113.03M
Selling, General & Admin12.36M21.12M29.38M127.91M23.3M
Operating Expenses12.34M21.12M219.83M329.36M133.84M
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
EBITDA(75.37M)(125.82M)(206.69M)1.7B(132.54M)
EBITDA Margin-1057.8%-5739.8%-11482.9%851675.0%-10195.5%
Operating Income(76.56M)(129.12M)(219.22M)(331.45M)(135.03M)
Operating Margin-1074.6%-5890.4%-12178.9%-165724.0%-10386.5%
Interest Income5.22M16.11M11.92M10.94M7.55M
Interest Expense5.22M16.11M31.84M13.49M12.2M
Other Income / Expenses(5.2M)(16.11M)(20.5M)2.02B(5.03M)
Income Before Tax(81.77M)(145.22M)(239.72M)1.69B(140.05M)
Pre-Tax Margin-1147.6%-6625.1%-13318.0%843787.0%-10773.3%
Income Tax Expense2K3K3K2K2K
Net Income(81.77M)(145.23M)(241.36M)1.69B(140.06M)
Net Margin-1147.6%-6625.3%-13408.9%843786.0%-10773.5%
EPS (Basic)(2.15)(3.62)(5.12)116.58(9.04)
EPS (Diluted)(2.15)(3.62)(5.12)116.58(9.04)
Weighted Avg Shares38.01M40.11M47.13M14.48M15.49M
Weighted Avg Shares (Diluted)38.01M40.11M47.13M14.48M15.49M

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.